open access

Vol 16, No 6 (2020)
Guidelines / Expert consensus
Published online: 2021-01-12
Get Citation

Rectal cancer (C20)

Krzysztof Bujko, Piotr Potemski, Andrzej Rutkowski, Jarosław Reguła, Andrzej Mróz, Anna Hołdakowska, Joanna Socha, Maciej Krzakowski
DOI: 10.5603/OCP.2020.0042
·
Oncol Clin Pract 2020;16(6):338-357.

open access

Vol 16, No 6 (2020)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT
Published online: 2021-01-12

Abstract

.

Abstract

.

Get Citation

Keywords

rectal cancer; diagnosis; treatment; follow-up; recommendations

About this article
Title

Rectal cancer (C20)

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 6 (2020)

Article type

Guidelines / Expert consensus

Pages

338-357

Published online

2021-01-12

DOI

10.5603/OCP.2020.0042

Bibliographic record

Oncol Clin Pract 2020;16(6):338-357.

Keywords

rectal cancer
diagnosis
treatment
follow-up
recommendations

Authors

Krzysztof Bujko
Piotr Potemski
Andrzej Rutkowski
Jarosław Reguła
Andrzej Mróz
Anna Hołdakowska
Joanna Socha
Maciej Krzakowski

References (73)
  1. Lakkis Z, Manceau G, Bridoux V, et al. French Research Group of Rectal Cancer Surgery (GRECCAR) and the French National Society of Coloproctology (SNFCP). Management of rectal cancer: the 2016 French guidelines. Colorectal Dis. 2017; 19(2): 115–122.
  2. Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28 Suppl 4(suppl_4): iv22–iv40.
  3. National Comprehensive Cancer Network, Rectal Cancer, Version 6.2020; https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (dostęp z dnia 29.06.2020r).
  4. Beets G, Sebag-Montefiore D, Andritsch E, et al. ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. Crit Rev Oncol Hematol. 2017; 110: 81–93.
  5. Williams JG, Pullan RD, Hill J, et al. Association of Coloproctology of Great Britain and Ireland. Management of the malignant colorectal polyp: ACPGBI position statement. Colorectal Dis. 2013; 15 Suppl 2: 1–38.
  6. Ferlitsch M, Moss A, Hassan C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2017; 49(3): 270–297.
  7. Hassan C, Wysocki PT, Fuccio L, et al. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline. Endoscopy. 2019; 51(3): 266–277.
  8. Morino M, Risio M, Bach S, et al. European Association for Endoscopic Surgery, European Society of Coloproctology. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc. 2015; 29(4): 755–773.
  9. Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018; 28(4): 1465–1475.
  10. https://documents.cap.org/protocols (dostęp z dnia 17.08.2020r).
  11. NICE. Colorectal cancer (update). (C4) Deferral of surgery in people having neoadjuvant therapy for rectal cancer. NICE guideline NG151 evidence reviews. January, 2020. https://www.nice.org.uk/guidance/ng151/evidence/evidence-reviews-january-2020-7029391213?tab=evidence (dostęp z dnia 29.06.2020r).
  12. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. Dostępne na stronie http://onkologia.org.pl/raporty (dostęp z dnia 05.08.2020r).
  13. Holleczek B, Rossi S, Domenic A, et al. EUROCARE-5 Working Group:. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study. Eur J Cancer. 2015; 51(15): 2158–2168.
  14. DʼSouza N, de Neree Tot Babberich MPM, d'Hoore A, et al. Definition of the Rectum: An International, Expert-based Delphi Consensus. Ann Surg. 2019; 270(6): 955–959.
  15. , et al Potemski P, Bujko K, Rutkowski A, Krzakowski M. Wytyczne postępowania diagnostyczno-terapeutycznego u chorych na raka okrężnicy (C18) i zagięcia esiczo-odbytniczego (C19). Dostępne na stronie https://journals.viamedica.pl/onkologia_w_praktyce_klin_edu/article/view/70008; Opublikowany online: 16.07.2020r.
  16. Battersby NJ, How P, Moran B, et al. MERCURY II Study Group. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg. 2016; 263(4): 751–760.
  17. Brouwer NPM, Stijns RCH, Lemmens VE, et al. Clinical lymph node staging in colorectal cancer; a flip of the coin? Eur J Surg Oncol. 2018; 44(8): 1241–1246.
  18. Amin BA, Edge SB. AJCC cancer staging manual. 8th ed. Springer, New York 2017.
  19. Spychalski M, Kamiński MF. Endoskopowa dyssekcja podśluzówkowa – evidence based medicine. Gastroenterologia Kliniczna. 2019; 11: 16–20.
  20. van der Valk MJM, Hilling DE, Bastiaannet E, et al. IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018; 391(10139): 2537–2545.
  21. Kusters M, Slater A, Betts M, et al. The treatment of all MRI-defined low rectal cancers in a single expert centre over a 5-year period: is there room for improvement? Colorectal Dis. 2016; 18(11): O397–O404.
  22. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008; 26(22): 3687–3694.
  23. Ciseł B, Pietrzak L, Michalski W, et al. Polish Colorectal Study Group. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019; 30(8): 1298–1303.
  24. Radu C, Berglund A, Påhlman L, et al. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008; 87(3): 343–349.
  25. Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 2013; 100(8): 1009–1014.
  26. Frykholm GJ, Isacsson U, Nygård K, et al. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993; 36(6): 564–572.
  27. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17): 1731–1740.
  28. Peeters KC, Marijnen CAM, Nagtegaal ID, et al. Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007; 246(5): 693–701.
  29. Sebag-Montefiore D, Stephens R, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009; 373(9666): 811–820.
  30. Birgisson H, Påhlman L, Gunnarsson U, et al. Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005; 23(34): 8697–8705.
  31. Peeters KC, van de Velde CJH, Leer JWH, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol. 2005; 23(25): 6199–6206.
  32. Holm T, Singnomklao T, Rutqvist LE, et al. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer. 1996; 78(5): 968–976, doi: 10.1002/(SICI)1097-0142(19960901)78:5<968::AID-CNCR5>3.0.CO;2-8.
  33. Marijnen CAM, van de Velde CJH, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005; 23(9): 1847–1858.
  34. Jørgensen JB, Bondeven P, Iversen LH, et al. Pelvic insufficiency fractures frequently occur following preoperative chemo-radiotherapy for rectal cancer - a nationwide MRI study. Colorectal Dis. 2018; 20(10): 873–880.
  35. Wiltink LM, Nout RA, Fiocco M, et al. No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. J Clin Oncol. 2015; 33(15): 1640–1646.
  36. NICE. Colorectal cancer (update). (C2) Preoperative radiotherapy and chemoradiotherapy for rectal cancer. NICE guideline NG151 evidence reviews. January, 2020. https://www.nice.org.uk/guidance/ng151/evidence/evidence-reviews-january-2020-7029391213?tab=evidence (dostęp z dnia 29.06.2020r).
  37. Glynne-Jones R, Harrison M, Cheetham D. NICE guideline for rectal cancer: already out of date. Lancet. 2020; 395(10240): e105–e106.
  38. Chand M, Siddiqui MRS, Swift I, et al. Systematic review of prognostic importance of extramural venous invasion in rectal cancer. World J Gastroenterol. 2016; 22(4): 1721–1726.
  39. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017; 18(3): 336–346.
  40. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10): 1215–1223.
  41. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31): 3827–3833.
  42. Pettersson D, Holm T, Iversen H, et al. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg. 2012; 99(4): 577–583.
  43. Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009; 92(2): 210–214.
  44. Hospers G, Bahadoer R, Dijkstra E, et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. Journal of Clinical Oncology. 2020; 38(15_suppl): 4006.
  45. Wiśniowska K, Nasierowska-Guttmejer A, Polkowski W, et al. Polish Colorectal Study Group. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study. Eur J Surg Oncol. 2016; 42(12): 1859–1865.
  46. van der Valk MJM, Marijnen CAM, van Etten B, et al. Collaborative investigators, Collaborative investigators. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. Radiother Oncol. 2020; 147: 75–83.
  47. Ogura A, Konishi T, Beets G, et al. Lateral nodal features on restaging magnetic resonance imaging associated with lateral local recurrence in low rectal cancer after neoadjuvant chemoradiotherapy or radiotherapy. JAMA Surg. 2019; 154(9): e192172.
  48. Sanfilippo NJ, Crane CH, Skibber J, et al. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. Int J Radiat Oncol Biol Phys. 2001; 51(1): 176–183.
  49. Syk E, Torkzad MR, Blomqvist L, et al. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys. 2008; 72(3): 658–664.
  50. Nijkamp J, Kusters M, Beets-Tan RGH, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys. 2011; 80(1): 103–110.
  51. Socha J, Pietrzak L, Zawadzka A, et al. A systematic review and meta-analysis of pT2 rectal cancer spread and recurrence pattern: Implications for target design in radiation therapy for organ preservation. Radiother Oncol. 2019; 133: 20–27.
  52. Peters FP, Teo MTW, Appelt AL, et al. Mesorectal radiotherapy for early stage rectal cancer: A novel target volume. Clin Transl Radiat Oncol. 2020; 21: 104–111.
  53. Wang Y, Cummings B, Catton P, et al. Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol. 2005; 77(2): 126–132.
  54. Sprawka A, Pietrzak L, Garmol D, et al. Definitive radical external beam radiotherapy for rectal cancer: evaluation of local effectiveness and risk of late small bowel damage. Acta Oncol. 2013; 52(4): 816–823.
  55. Rijkmans EC, Marijnen CAM, van Triest B, et al. Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study. Int J Radiat Oncol Biol Phys. 2017; 98(4): 908–917.
  56. Heald RJ, Beets G, Carvalho C. Report from a consensus meeting: response to chemoradiotherapy in rectal cancer - predictor of cure and a crucial new choice for the patient: on behalf of the Champalimaud 2014 Faculty for 'Rectal cancer: when NOT to operate'. Colorectal Dis. 2014; 16(5): 334–337.
  57. Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018; 3(12): 825–836.
  58. Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2(7): 501–513.
  59. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11(9): 835–844.
  60. Bujko K, Michalski W, Kepka L, et al. Polish Colorectal Study Group. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys. 2007; 67(2): 369–377.
  61. Socha J, Kępka L, Michalski W, et al. The risk of distant metastases in rectal cancer managed by a watch-and-wait strategy - A systematic review and meta-analysis. Radiother Oncol. 2020; 144: 1–6.
  62. Smith FM, Rao C, Oliva Perez R, et al. Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: results of a decision-analytic model. Dis Colon Rectum. 2015; 58(2): 159–171.
  63. Bujko K, Wyrwicz L, Rutkowski A, et al. Polish Colorectal Study Group. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016; 27(5): 834–842.
  64. Conroy T, Lamfichekh N, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2020; 38(15_suppl): 4007.
  65. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16(2): 200–207.
  66. Bujko K, Glimelius B, Valentini V, et al. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin. Eur J Surg Oncol. 2015; 41(6): 713–723.
  67. Poulsen LØ, Qvortrup C, Pfeiffer P, et al. Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much? Acta Oncol. 2015; 54(4): 437–446.
  68. Hong YS, Kim SY, Lee JiS, et al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. J Clin Oncol. 2019; 37(33): 3111–3123.
  69. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014; 101(10): 1280–1289.
  70. Valentini V, Morganti AG, Gambacorta MA, et al. Study Group for Therapies of Rectal Malignancies (STORM). Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006; 64(4): 1129–1139.
  71. Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol. 2014; 113(2): 151–157.
  72. Tyc-Szczepaniak D, Wyrwicz L, Kepka L, et al. Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. Ann Oncol. 2013; 24(11): 2829–2834.
  73. van Dijk TH, Tamas K, Beukema JC, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013; 24(7): 1762–1769.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl